In a prespecified exploratory analysis of ACACIA-HCM (517 patients with symptomatic nonobstructive HCM), aficamten vs placebo improved diastolic measures (lateral e' +0.9 cm/s at 36 weeks) and lowered LVEF by 4.6%; LA volume index did not significantly improve at 36 weeks.
Secondary analysisn = 517
Hegde et al. Effect of Aficamten on Cardiac Structure and Function in Patients With Symptomatic Nonobstructive Hypertrophic Cardiomyopathy